Resume

AI governance and assurance for life sciences and healthcare. Albuquerque, New Mexico; remote, U.S. Updated September 2026.

Download the PDF Plain-text version

Summary

AI governance and assurance for regulated life sciences and healthcare: governance design for agentic systems and evaluation against specification. Specified the governance design of a multi-institution agentic system; designed and built a multi-agent evaluation instrument (rubrics committed before any run, sealed targets, split-context and single-context arms, leakage review, provenance export of every turn); commissioned an origin-blind adversarial audit of it, one model producing findings with no knowledge of who built it and a second confirming each against the source, and maintain the versioned defect register; authored Tension OS v2.1, a decision and governance methodology with conformance cross-walks to the EU AI Act, ISO/IEC 42001 and NIST AI RMF. The judgment to specify the system and build the instrument came from prior experience: academic research at MD Anderson and Albert Einstein College of Medicine (co-author, ACS Medicinal Chemistry Letters); lab operations at Identigene; eleven years of testing healthcare-access business models and four years of launching and managing two business ventures; an MBA; bilingual English and Spanish.

Experience

• Jul 2025 – presentFounder, SyncOrch: AI-mediated research-collaboration platform (Albuquerque; remote). Governance, evaluation and assurance work product: the governance design of the multi-institution system; the v3 instrument and its audit; Tension OS v2.1; Keel.
• Aug 2014 – Dec 2025Founder, Patient Support Network: healthcare-access and patient-financing venture (New York, Houston, Philadelphia). Successive models (I Help Today, Celyco, PSN) taken to institutional review; PSN-AI prototype in 2025; converged into SyncOrch in July 2025 and closed in December 2025.
• Aug 2014 – May 2016MBA, Yeshiva University, Sy Syms School of Business.
• Sep 2013 – Jun 2014Laboratory Technician, Albert Einstein College of Medicine: preclinical lung- and pancreatic-cancer therapeutics research (autophagy inhibition). Co-author, ACS Medicinal Chemistry Letters (2014): Discovery of Autophagy Inhibitors with Antiproliferative Activity in Lung and Pancreatic Cancer Cells.
• May 2008 – Oct 2012Founder and Operations Manager, Mizonett Companies (Houston; San Juan): nonprofit fundraising events (a City of Houston Proclamation for the largest) and homeowners association (HOA) management under three contracts covering about 800 residential units: budgets, collections, vendors, board governance, local regulatory compliance.
• Nov 2007 – Apr 2008Laboratory Technician, Identigene (Houston): high-volume DNA parentage testing operations: sample receipt and preparation, PCR, and capillary analysis, run as a daily production pipeline across hundreds of client samples.
• Aug 2006 – Jul 2007Graduate Research Assistant, UT MD Anderson Cancer Center / UTHealth Graduate School of Biomedical Sciences: doctoral coursework and three research rotations in cancer biology, including early work on a STAT3-inhibitor program that later reached publication.
• Aug 2000 – May 2006BS, Natural Sciences, University of Puerto Rico, Río Piedras. Summer research: Weill Cornell / Memorial Sloan Kettering ACCESS Summer Research Program (2003) and MD Anderson Summer Research Program (2004).

Frameworks and methods

AI governance; AI assurance and audit; Responsible AI; AI risk management; evaluation design and LLM evaluation; red-teaming; agentic AI governance; open-weight model admission; EU AI Act; ISO/IEC 42001; NIST AI RMF; conformance assessment; human oversight; logging and telemetry; decision records; documentation discipline.